MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA
Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.
Insurance Delays Add Costs to CAR T-Cell Therapy: Ravi Vij, MD, MBA
Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.
CAR T and Bispecifics Pose Different Challenges in Blood Cancer Treatment: Ravi Vij, MD, MBA
Ravi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.
